3M Company vs ResMed Inc. — how do they compare? 3M Company trades at $183.06 (market cap $93.88B), while ResMed Inc. trades at $223.62 (market cap $31.92B). The key difference: 3M Company is far larger — about 2.9× ResMed Inc.'s market cap, and 3M Company pays the higher dividend (1.71%). Which is the better fit depends on your goals.
| MMM | RMD | |
|---|---|---|
Market Cap | $93.88B | $31.92B |
Sector | Industrials | Health |
52-Week High | $183.13 | $293.73 |
52-Week Low | $141.10 | $182.82 |
Enterprise Value | $103.10B | $31.28B |
Dividend Yield | 1.71% | 1.2% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →